ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Changes in Registrant’s Certifying Accountant

ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant.

Story continues below

Resignation of Current Independent Registered Public Accounting Firm

On June22, 2018, Rockwell Medical Inc.’s (the “Company”) independent accountant, Plante& Moran, PLLC (“Plante”), notified the Chair of the Audit Committee of the Board of Directors that it was resigning as the Company’s independent registered public accounting firm, effective immediately.

Plante’s reports on the Company’s financial statements for the years ended December31, 2016 and December31, 2017 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles.

During the two most recent years ended December31, 2016 and December31, 2017 and through June22, 2018 (the date of Plante’s resignation), the Company had no disagreements with Plante on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Plante’s satisfaction, would have caused it to make reference to the subject matter of the disagreements in connection with its reports.

In its letter to the Audit Committee dated June22, 2018, which is attached hereto as Exhibit99.2 and was issued by Plante in conjunction with its resignation letter, Plante identified certain reportable events, as described in Item 304(a)(1)(v)of Regulation S-K, relating to the Company’s financial statements and disclosures contained in the Company’s Quarterly Report on Form10-Q for the period ended March31, 2018 (the “Form10-Q”). The terms of this letter are incorporated herein by reference.

The Chairman of the Audit Committee as well as another member of the Audit Committee, the Chairman of the Board, discussed with Plante the reasons for its resignation and has authorized Plante to respond fully to the inquiries of the Company’s successor independent registered public accounting firm concerning the reasons for Plante’s resignation.

The Company has provided Plante with a copy of the disclosures made in this Current Report on Form8-K prior to the time this report was filed with the Securities and Exchange Commission. The Company has requested that Plante furnish a letter addressed to the Securities and Exchange Commission stating whether it agrees with the Company’s statements made in this report. A copy of Plante’s letter dated June26, 2018, is attached as Exhibit16.1 hereto.

Plante has not provided notice to the Company that disclosure should be made or action should be taken to prevent future reliance on the completed interim review related to the previously issued financial statements contained in the Form10-Q. The Audit Committee is in the process of reviewing the concerns set forth in Plante’s correspondence and has not made a determination as to whether the financial statements in the Form10-Q should not be relied upon. If the Audit Committee determines that the financial statements should not be relied upon, this conclusion will be reported in a separate Current Report on Form8-K.

Engagement of New Independent Registered Public Accounting Firm

As of the date of this report, the Audit Committee has not yet retained a new independent registered public accounting firm. The Audit Committee is in the process of identifying and selecting a new independent registered public accounting firm and will disclose the selection when made on a subsequent Current Report on Form8-K.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits. The following exhibits are being filed herewith:

EX-16.1 2 a18-16122_1ex16d1.htm EX-16.1 Exhibit 16.1   June 26,…
To view the full exhibit click here


Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

An ad to help with our costs